Reading this on a mobile device? Try our optimized mobile version here:

November 6, 2012
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
Macrocycle Diary's New Entry: Ensemble Deal with Boehringer
By entering a potential $186 million research pact with Ensemble Therapeutics Inc. for synthetic macrocycles, Boehringer Ingelheim GmbH became the latest to place its bet on a newish, challenging approach that could combine the all-in-all pill possibility of small molecules with the biological bull's-eye talent of large ones. Find out the details.

  Health Care & Policy 
  • BioMarin's experimental MPS IVA drug meets main endpoint in trial
    A late-stage trial found that BioMarin Pharmaceutical's enzyme replacement therapy GALNS, or N-acetylgalactosamine-6 sulfatase, helped patients with mucopolysaccharidosis IVA walk 22.5 meters farther in six minutes, the primary goal of the study, compared with placebo. BioMarin plans to apply for regulatory approval next year. Bloomberg (11/5), BioWorld Online (free registration) (11/5) LinkedInFacebookTwitterEmail this Story
  • Amgen's cholesterol drug performs well in Phase II study
    Patients with heterozygous familial hypercholesterolemia who received Amgen's investigational drug AMG145 plus statins saw their LDL, or "bad," cholesterol levels drop by up to 55% compared with patients who took a placebo during a midstage trial. AMG145 is designed to target the PCSK9 protein, which stops the body from eliminating LDL cholesterol from the bloodstream. Reuters (11/5) LinkedInFacebookTwitterEmail this Story
  • Pharma takes risk with vulnerable "product shots"
    Interest in finding the next blockbuster drug prompts major pharmaceutical firms to risk significant amounts of money and resources in huge, individual development programs, or "product shots," Forbes contributor David Shaywitz writes. Drugmakers have a better chance of success with numerous small drug development programs, he writes. Forbes (11/5) LinkedInFacebookTwitterEmail this Story
  • Stem cell treatment shows promise for sperm function
    A study in the journal Cell Stem Cell found that sperm-producing stem cells taken from monkeys before chemotherapy can be returned after treatment to improve reproductive function. The method resulted in working sperm from three out of five prepubescent monkeys and nine out of 12 mature monkeys. BBC (11/1) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  Global Developments 
  • U.K. allots $16M for creation of synthetic biology center
    The U.K. plans to allocate $16 million over five years to establish an Innovation and Knowledge Centre in Synthetic Biology to aid the development and market launch of synthetic biology technologies. The Biotechnology and Biological Sciences Research Council, which will support the funding program along with the Technology Strategy Board and the Engineering and Physical Sciences Research Council, is inviting institutions to submit their proposals. GenomeWeb Daily News (free registration) (11/2) LinkedInFacebookTwitterEmail this Story

Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or 

  Food & Agriculture 
  • Scientists develop tomato that could fight heart disease
    Scientists from the University of California at Los Angeles have developed a tomato that produces a peptide that imitates the main protein in good cholesterol. Mice fed with the modified tomatoes had less inflammation and atherosclerosis. "We have found a new and practical way to make a peptide that acts like the main protein in good cholesterol, but is many times more effective and can be delivered by eating the plant," said Dr. Alan Fogelman, head of the department of medicine at UCLA. HealthDay News (11/5), Daily Express (London) (11/6) LinkedInFacebookTwitterEmail this Story
  Industrial & Environmental 
  • Researchers find quick way to convert algae into biocrude
    Researchers at the University of Michigan have found a way to turn marine algae into biocrude by "pressure cooking" it in intense heat for as little as one minute. "My guess is that the reactions that produce biocrude are actually much faster than previously thought," said Phil Savage, a chemical engineering professor. The researchers emphasized the need for further study. (11/2) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • BIOtechNOW
    BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

It's impossible to move, to live, to operate at any level without leaving traces, bits, seemingly meaningless fragments of personal information."
--William Gibson,
American-Canadian author

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information